ArticleBMC cancer2022

Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia.

Nicole Bourrier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.